Abstract
Background:
PCC (Kcentra®) is an Food and Drug Administration (FDA)–approved 4-factor PCC used for the treatment of warfarin-related coagulopathy (WRC), but it has also been used off-label to treat non-WRC. Three-factor PCC in the form of coagulation factor IX human (Bebulin®) has also been used for WRC and off-label to treat non-WRC. It is unclear whether the use of 3- or 4-factor PCCs is effective for the treatment of non-WRC,.
Objective:
Our aim is to characterize the use of 3- and 4-factor PCCs for patients identified with a non-WRC.
Methods:
A retrospective analysis of patients who received PCCs for both WRC and non-WRC between January 2012 and July 2015 was conducted.
Results:
A total of 187 patients with elevated international normalized ratio (INR) who received PCCs were analyzed; 53.9% of patients in the WRC group and 27.7% in the non-WRC group corrected to an INR of 1.3 or less after 3- or 4-factor PCC administration. In those patients with non-WRC and who had underlying liver disease, 3- and 4-factor PCCs reduced mean INR by 0.98 and 1.43, respectively.
Conclusion:
Three and 4-factor PCCs can reduce INR in patients with WRC and in those with non-WRC secondary to liver disease.
Get full access to this article
View all access options for this article.